Business Context and Reporting Period
This Form 8-K reports on the 2016 Annual Meeting of Shareholders held by OncoCyte Corporation on June 9, 2016. The filing details the election of directors and the ratification of the independent registered public accountants.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and shareholder voting results.
Material Changes and Voting Results
Shareholders voted on two primary matters at the annual meeting:
- Shareholder Participation: 24,191,446 shares (95.7% of voting power) were represented at the meeting out of 25,285,743 eligible shares.
- Election of Directors: Seven directors were elected. All nominees received significant support, with votes withheld ranging from approximately 46,000 to 122,000 per nominee. There were 1,675,656 broker non-votes on this matter.
- Ratification of Accountants: The appointment of OUM & Co. LLP as independent auditors was ratified with 24,147,832 votes for, 8,485 against, and 35,129 abstentions. There were no broker non-votes on this matter.
Guidance, Outlook, and Risks
The filing includes a standard forward-looking statements disclaimer, noting that actual results may differ materially from anticipated results due to risk factors detailed in the company's Form 10. No specific financial guidance, management commentary on operations, or new contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the full list of elected directors and their tenure terms in the company's proxy statement.
- Review the Form 10 filing referenced in the document for detailed risk factors and financial performance data.
- Confirm the independence and qualifications of OUM & Co. LLP as the newly ratified auditor.